Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarpogrelate vs Clopidogrel for ABI in Stroke Patients with PAD
NCT06424548Not yet recruiting
- Sponsor
- Ewha Womans University Seoul Hospital
- Start
- May 2024
- Primary completion
- Jun 2028
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of sarpogrelate in Peripheral Arterial Disease (PAD) and intermittent claudication (IC) (2 arms), sponsored by Ewha Womans University Seoul Hospital. Primary endpoint: Ankle Brachial Index at 12 months. Planned start May 2024; status: not yet recruiting.
02
Drugs
sarpogrelate
03
Conditions
Peripheral Arterial Disease (PAD)intermittent claudication (IC)
Beyond the preview
Go deeper on NCT06424548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06424548.